These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 19682084

  • 1. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
    Drexel H.
    Fundam Clin Pharmacol; 2009 Dec; 23(6):687-92. PubMed ID: 19682084
    [Abstract] [Full Text] [Related]

  • 2. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
    Goumas GS.
    Angiology; 2009 Dec; 60(1):93-8. PubMed ID: 19019838
    [Abstract] [Full Text] [Related]

  • 3. [Therapy of dyslipidemia in post-infarction: state of the art].
    Borgia MC, Nardi M, Da Ros S, Castellano V.
    Clin Ter; 2007 Dec; 158(6):523-32. PubMed ID: 18265719
    [Abstract] [Full Text] [Related]

  • 4. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 5. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

  • 6. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D, Velkeniers B, Duquet W, Betz W.
    Int J Cardiol; 2005 May 25; 101(2):231-5. PubMed ID: 15882669
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES.
    J Am Coll Cardiol; 2005 Jan 18; 45(2):185-97. PubMed ID: 15653014
    [Abstract] [Full Text] [Related]

  • 8. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    Brown BG, Zhao XQ.
    Am J Cardiol; 2008 Apr 17; 101(8A):58B-62B. PubMed ID: 18375243
    [Abstract] [Full Text] [Related]

  • 9. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P.
    Am J Manag Care; 2009 Mar 17; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [Abstract] [Full Text] [Related]

  • 10. Managing dyslipidemia in chronic kidney disease.
    Harper CR, Jacobson TA.
    J Am Coll Cardiol; 2008 Jun 24; 51(25):2375-84. PubMed ID: 18565393
    [Abstract] [Full Text] [Related]

  • 11. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R, Goldberg AC.
    Endocrinol Metab Clin North Am; 2009 Mar 24; 38(1):79-97. PubMed ID: 19217513
    [Abstract] [Full Text] [Related]

  • 12. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK.
    Atherosclerosis; 2015 Oct 24; 242(2):647-56. PubMed ID: 26296750
    [Abstract] [Full Text] [Related]

  • 13. Lipid management in the geriatric patient.
    Nair AP, Darrow B.
    Endocrinol Metab Clin North Am; 2009 Mar 24; 38(1):185-206. PubMed ID: 19217519
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Advances in cholesterol-lowering interventions].
    Ascaso JF.
    Endocrinol Nutr; 2010 May 24; 57(5):210-9. PubMed ID: 20451478
    [Abstract] [Full Text] [Related]

  • 16. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M.
    Dtsch Med Wochenschr; 2009 May 24; 134(20):1067-73. PubMed ID: 19421932
    [Abstract] [Full Text] [Related]

  • 17. Strategies for reducing cardiovascular risk in patients with hypertriglyceridemia.
    Gorkin JU, Watson K, Knopp RH.
    J Fam Pract; 2007 Aug 24; 56(8 Suppl Strategies):S1-7; quiz S8. PubMed ID: 18667138
    [No Abstract] [Full Text] [Related]

  • 18. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH.
    Am J Cardiol; 2008 Dec 22; 102(12A):41L-47L. PubMed ID: 19084089
    [Abstract] [Full Text] [Related]

  • 19. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E, Davidson MH.
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr 22; 16(2):183-8. PubMed ID: 19262375
    [Abstract] [Full Text] [Related]

  • 20. Beyond blood lipids: phytosterols, statins and omega-3 polyunsaturated fatty acid therapy for hyperlipidemia.
    Micallef MA, Garg ML.
    J Nutr Biochem; 2009 Dec 22; 20(12):927-39. PubMed ID: 19733044
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.